Table 1

Baseline patient characteristics*

CharacteristicsFull population (n = 16,488)TRS 2°P
≤2 (n = 4,034 [24.5%])3 (n = 5,516 [33.5%])4 (n = 4,221 [25.6%])≥5 (n = 2,717 [16.5%])
Age (years)65.0 (60.0–71.0)63.0 (59.0–68.0)64.0 (58.0–69.0)66.0 (60.0–73.0)71.0 (63.0–77.0)
Female, n (%)5,454 (33.1)1,468 (36.4)1,852 (33.6)1,328 (31.5)806 (29.7)
Age >65 years, n (%)7,821 (47.4)1,503 (37.3)2,292 (41.6)2,210 (52.4)1,816 (66.8)
BMI (kg/m2)30.5 (27.2–34.4)30.5 (27.3–34.5)30.4 (27.1–34.4)30.4 (27.2–34.4)30.6 (27.4–34.5)
Hypertension, n (%)13,492 (81.8)2,397 (59.4)4,677 (84.8)3,852 (91.3)2,566 (94.4)
Dyslipidemia, n (%)11,738 (71.2)2,674 (66.3)3,794 (68.8)3,135 (74.3)2,135 (78.6)
Established atherosclerotic disease, n (%)13,139 (79.7)2,002 (49.6)4,489 (81.4)3,957 (93.7)2,691 (99.0)
CAD, n (%)10,276 (62.3)1,577 (39.1)3,245 (58.8)3,075 (72.9)2,379 (87.6)
Prior MI, n (%)6,236 (37.8)459 (11.4)1,816 (32.9)2,083 (49.3)1,878 (69.1)
Prior PCI >1 artery, n (%)4,039 (24.5)911 (22.6)1,309 (23.7)1,060 (25.1)759 (27.9)
Prior coronary revascularization, n (%)7,122 (43.2)1,041 (25.8)2,088 (37.9)2,147 (50.9)1,846 (67.9)
PAD, n (%)1,958 (11.9)156 (3.9)562 (10.2)604 (14.3)636 (23.4)
Prior heart failure, n (%)2,105 (12.8)18 (0.4)245 (4.4)696 (16.5)1,146 (42.2)
Prior atrial fibrillation, n (%)1,202 (7.3)139 (3.4)289 (5.2)372 (8.8)402 (14.8)
Prior ischemic stroke, n (%)2,094 (12.7)130 (3.2)697 (12.6)663 (15.7)604 (22.2)
Current smoker, n (%)2,219 (13.5)146 (3.6)676 (12.3)821 (19.5)576 (21.2)
eGFR (mL/min/1.73 m2)71.7 (57.1–86.4)80.6 (70.4–94.0)75.2 (63.7–89.2)64.4 (51.9–81.8)53.3 (43.0–64.7)
Glycated hemoglobin, %; mmol/mol7.6 (6.9–8.7); 60 (52–72)7.6 (6.9–8.7); 60 (52–72)7.7 (6.9–8.8); 61 (52–73)7.7 (7.0–8.8); 61 (53–73)7.6 (7.0–8.6); 60 (53–70)
Saxagliptin, n (%)8,278 (50.2)2,074 (51.4)2,762 (50.1)2,051 (48.6)1,391 (51.2)
  • Continuous variables are presented as median (quartile 1–quartile 3). eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention.

  • *All P values <0.05 except for BMI and saxagliptin assignment.